Quanterix Announces Comprehensive Board and Leadership Enhancements to Accelerate Its Next Phase of Strategic Growth
Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a global leader in ultrasensitive biomarker detection and a pioneer in translating biomarker discoveries into impactful diagnostic solutions, today announced a broad set of leadership and governance changes designed to reinforce the Company’s strategic direction and fuel its next stage of growth. These enhancements reflect Quanterix’s commitment to strengthening its scientific, operational, and commercial capabilities as it advances biomarker innovation from discovery through clinical use.
A central element of today’s announcement is the appointment of two highly respected life sciences leaders—Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D.—to the Company’s Board of Directors, effective immediately. Both executives bring decades of expertise across molecular diagnostics, genomics, translational research, and product innovation, and each has played influential roles at leading global biotechnology organizations.
Dr. Hampton most recently served as President of the Clinical Next-Generation Sequencing and Oncology division at Thermo Fisher Scientific, where he oversaw broad portfolios in clinical sequencing, oncology diagnostics, and precision medicine solutions. His leadership has spanned cutting-edge technologies, regulatory-compliant platforms, and large-scale commercialization initiatives. Dr. Sachs, who also spent many years at Thermo Fisher Scientific, previously held the roles of Chief Medical Officer and Chief Scientific Officer. Across his career, Dr. Sachs has led scientific strategy, R&D programs, and cross-functional teams working at the intersection of clinical research, diagnostics, and emerging therapeutic technologies. Their combined expertise positions them to make immediate and lasting contributions to Quanterix’s Board as the Company advances a more expansive biomarker and diagnostics strategy.
In addition to these new appointments, Quanterix announced several important leadership transitions within its Board structure. Bill Donnelly, who has served as the non-Executive Chair of the Board, has been named Executive Chair. In this expanded role, Mr. Donnelly will work in close partnership with the Company’s leadership team, lending strategic oversight and targeted operational support as Quanterix scales its scientific and commercial platforms. His appointment aligns with the Company’s increasing focus on structured execution and long-term growth acceleration.
The Company also announced that current Board member Jeffrey Elliott has been appointed Lead Independent Director, a newly created position. In this role, Mr. Elliott will support enhanced governance, strengthen alignment between management and the independent directors, and ensure strong Board oversight as Quanterix navigates a period of strategic expansion.
Together, these governance enhancements are intended to support Chief Executive Officer Masoud Toloue and the broader leadership team as they advance key priorities and drive the integration of recent strategic initiatives. These priorities include expanding the Company’s blood- and tissue-based biomarker assay menu, scaling adoption of its ultrasensitive detection technologies, launching the LucentAD Complete™ diagnostic offering to support Alzheimer’s disease evaluation, and accelerating operational and commercial synergies following Quanterix’s acquisition of Akoya Biosciences.
As part of its Board refresh, Quanterix also announced the departure of two long-serving directors, Paul Meister and David Walt, Ph.D., both of whom are stepping down from the Board effective immediately. Their departures mark the conclusion of highly impactful tenures during which each helped shape the Company’s scientific direction, growth trajectory, and organizational development.
With these changes, Quanterix’s Board now consists of nine directors, seven of whom are independent under Nasdaq guidelines, reinforcing the Company’s commitment to strong corporate governance and balanced oversight.
Commenting on the new appointments, Bill Donnelly, Executive Chair of the Board, stated, “On behalf of the entire Company, I am delighted to welcome Garret and Alan to the Board. Their extensive experience in diagnostics, life sciences, and product innovation will bring invaluable insight to our governance structure. As we move beyond the integration phase of recent strategic initiatives and sharpen our focus on growth, their deep scientific understanding and commercial acumen will help guide our evolution. Both leaders have demonstrated impressive track records identifying growth opportunities and executing complex strategies, and we are confident their contributions will support the next chapter of Quanterix’s advancement.”
Mr. Donnelly also expressed his gratitude to the departing directors, adding, “I want to extend our deepest thanks to Paul and David for their many years of dedicated service. David, as our founding scientist and an internationally recognized pioneer in precision medicine, has been instrumental in shaping Quanterix’s core scientific principles and advancing innovations that have transformed disease detection and monitoring. Paul, a highly respected life sciences investor, has provided invaluable strategic direction and insight into capital markets, organizational development, and commercial strategy. Together, they have helped guide Quanterix through critical phases of its growth, and their impact will continue to be felt for years to come. We wish them both continued success in their future endeavors.”
Quanterix CEO Masoud Toloue also commented on the Board enhancements, emphasizing their significance in the context of the Company’s accelerating strategy. “I am thrilled to welcome Garret and Alan, two leaders with exceptional technical depth and business leadership experience. Their perspectives are deeply aligned with our mission to deliver innovative tools and diagnostic solutions that improve patient outcomes worldwide. Bill’s expanded role as Executive Chair will further strengthen the alignment between operational execution and long-term strategy, helping us accelerate progress across our priority programs. With this strengthened governance structure and expanded expertise, Quanterix is extremely well positioned to lead the next era of biomarker and diagnostics advancement.”
Mr. Donnelly echoed this sentiment, stating, “I look forward to partnering closely with Masoud and the leadership team as we continue advancing the Company’s strategic priorities. With the acquisition of Akoya Biosciences now completed and integration progressing smoothly, Quanterix is entering an exciting new chapter characterized by greater scale, broader capabilities, and growing market opportunity. The Board is confident in the Company’s ability to deliver meaningful value for shareholders, while also creating significant benefits for patients, research partners, clinicians, and the entire healthcare ecosystem.”
The leadership and governance enhancements announced today underscore Quanterix’s commitment to strengthening the organizational foundation required to drive sustained growth and execute on the Company’s ambitious vision. As the Company continues expanding its biomarker technologies, broadening its clinical diagnostics initiatives, and integrating newly acquired capabilities, these changes aim to ensure that Quanterix remains at the forefront of biomarker-driven innovation and next-generation precision diagnostic solutions.
Garret Hampton has more than 35 years of experience across life sciences, diagnostics, and oncology. From 2020 to 2024, he served as President of Clinical Next Generation Sequencing and Oncology at Thermo Fisher Scientific, Inc. (NYSE: TMO), where he led a 800-person division focused on oncology diagnostics. Prior to that, he was Senior Vice President of Clinical Genomics at Illumina, Inc. (NASDAQ: ILMN), and previously held senior leadership roles at Genentech, Celgene and the Genomics Institute of the Novartis Research Foundation. He currently serves as an independent director of IDEAYA Biosciences, Inc. (NASDAQ: IDYA). Dr. Hampton earned his Ph.D. in Genetics from University College London and his M.A. and B.S. Natural Science, Genetics, from Trinity College Dublin.
Alan Sachs has more than two decades of experience in molecular diagnostics and technology development. Most recently, he spent nine years at Thermo Fisher Scientific (NYSE: TMO), serving as Chief Medical Officer from 2021 to 2025 and Chief Scientific Officer from 2016 to 2021. In those roles, he led the company’s research and development efforts, championing innovation across disciplines and accelerating the adoption of diagnostic platforms and tests. Prior to that, he served as Vice President and Global Head of Research and Development at Life Technologies Corporation (formerly NASDAQ: LIFE), from 2012 to 2016.
Earlier in his career, he spent a decade at Merck Research Laboratories from 2001 to 2011, where he ran technology development and application, built and led global departments in RNA therapeutics, molecular profiling and translational sciences, and managed complex external collaborations. He began his career as a faculty member at The University of California, Berkeley, where he contributed to the advancement of molecular and cellular biology. Dr. Sachs holds an M.D. and a Ph.D. in Cell Biology from Stanford University and a B.A. in Biological Sciences from Cornell University.
Bill Donnelly has served as a member of the Quanterix Board since August 2023 and has served as Chair since March 2025. Mr. Donnelly has more than 30 years of leadership experience in the life sciences and industrial technology sectors. He spent most of his career at Mettler-Toledo International Inc. (NYSE: MTD). Prior to his retirement in 2018 after more than 20 years with the company, he served as Executive Vice President responsible for finance, investor relations, supply chain and information technology.
He joined Mettler-Toledo in 1997 as its Chief Financial Officer. Mr. Donnelly has been a director of Ingersoll Rand Inc. (NYSE: IR) since May 2017 and was appointed Lead Independent Director in November 2021. He has also served as a director of T. Rowe Price Group, Inc. (NASDAQ: TROW) since 2023. Mr. Donnelly holds a bachelor’s degree in business administration from John Carroll University.
Jeff Elliott has served as a member of the Quanterix Board since August 2024. Mr. Elliott has more than 20 years of experience in the diagnostics and life sciences industries, with deep expertise in finance, strategy and operations. Since September 2024, Mr. Elliott has served as a consultant to The Boston Consulting Group, Inc. From November 2016 to May 2024, he served as Chief Financial Officer of Exact Sciences Corporation (NASDAQ: EXAS) and as Chief Operating Officer from 2021 to 2023.
Prior to his appointment as CFO, he served as Vice President of Strategy and Business Development at Exact Sciences. Earlier in his career, Mr. Elliott was a senior equity research analyst at Robert W. Baird & Co., where he covered healthcare companies in the diagnostics and life sciences tools sectors. Since March 2025, he has been a director of Sera Prognostics, Inc. (NASDAQ: SERA). Mr. Elliott earned a B.S. in Business Administration from the University of Illinois at Urbana-Champaign and an M.B.A. from the University of Chicago Booth School of Business. He is also a Chartered Financial Analyst (CFA) charter holder.
Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.
Source Link: https://www.businesswire.com/
